| insulin peglispro (LY2605541) / Eli Lilly |
NCT01654380: A Study of LY2605541 Versus Insulin Glargine on Blood Sugar |
|
|
| Completed | 1 | 22 | US | LY2605541, Insulin glargine | Eli Lilly and Company | Healthy Volunteers, Diabetes Mellitus, Type 1 | 10/13 | 10/13 | | |
NCT01784211: A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes |
|
|
| Completed | 1 | 76 | Europe | LY2605541, Insulin Glargine | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 11/13 | 11/13 | | |
NCT01771250: A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes |
|
|
| Completed | 1 | 15 | Europe | Insulin Peglispro, LY2605541, Insulin Glargine | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 12/14 | 12/14 | | |
NCT02152384: A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements |
|
|
| Completed | 1 | 28 | Europe | Insulin Peglispro, LY2605541, Insulin Lispro, Insulin Glargine | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 12/14 | 12/14 | | |
NCT02109029: A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue |
|
|
| Completed | 1 | 24 | Europe | Insulin Peglispro, LY2605541, Human Insulin | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 03/15 | 03/15 | | |
NCT01925989: A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics |
|
|
| Completed | 1 | 27 | US | LY2605541, Insulin Glargine | Eli Lilly and Company | Type 1 Diabetes Mellitus | 10/15 | 10/15 | | |
BIDO, NCT02211586: Effects and Response of LY2605541 in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 62 | US | Insulin Glargine or LY2605541, Lantus or LY2605541 | Translational Research Institute for Metabolism and Diabetes, Florida, Eli Lilly and Company | Type 1 Diabetes Mellitus, Healthy | 12/15 | 03/16 | | |
